Company intelligence / Profile preview
TAP Pharmaceutical Products
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Other
Overview
TAP was highly successful with two key commercial products: lansoprazole (Prevacid) for acid-related diseases and leuprorelin (Lupron) for prostate cancer and other hormone-dependent conditions. The company also developed and marketed antibiotics and explored additional pipeline drugs, though some were withdrawn or discontinued.[1][3][5][7]
- Therapeutic areas
- OncologyInfectious DiseasesWomen's HealthNephrologyEndocrinologyGastroenterology
- Modalities
- Small moleculePeptides
- Industry
- Pharma
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on TAP Pharmaceutical Products.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAP Pharmaceutical Products.